IQVIA Holdings shares have rallied 41.5% over the past three months, outperforming the industry's 17.2% growth and the S&P 500's 3.4% uptick. The company reported net new bookings of $3.2 billion for research and development solutions in the second quarter of 2026, up 19% year over year and yielding a book-to-bill ratio of 1.22X. Its contracted backlog stood at $34.2 billion as of June 30, 2026, with $9.2 billion expected to convert to revenue in the next 12 months. Management raised full-year revenue guidance to $17.28-$17.48 billion and earnings guidance to $12.8-$13 per share. IQVIA repurchased $950 million of shares in the first half of 2026 after buying back $1.24 billion in 2025.
IQVIA Holdings Incraised guidance and strong bookings
Anika Therapeutics Inc
